# PT-141 FAQ: Research Questions Answered > PT-141 frequently asked questions: mechanism, dosage, side effects, FDA approval, half-life, and HSDD trial data — answered directly from the peer-reviewed literature. ## Frequently Asked Questions: PT-141 (Bremelanotide) These questions are answered directly from the bremelanotide clinical literature. Every quantitative claim below cites a source in the references index. PT-141 is the primary subject throughout. **What does the PT-141 peptide do?** PT-141 (bremelanotide) is a synthetic analogue of alpha-MSH that acts as an agonist at MC3R and MC4R receptors in the central nervous system, activating neural pathways associated with sexual arousal and desire. In the RECONNECT Phase 3 trials, it produced statistically significant improvements in satisfying sexual events and sexual distress measures in premenopausal women with HSDD versus placebo [5]. In Phase 2 male studies, it produced dose-dependent erectile responses [1, 2]. **What is PT-141?** PT-141 is a 7-amino-acid cyclic peptide (bremelanotide) derived from melanotan II, studied for its melanocortin receptor agonist activity and its effects on central nervous system pathways governing sexual arousal. Molecular weight 1025.2 Da, molecular formula C50H68N14O10. FDA-approved in 2019 under the trade name Vyleesi for HSDD in premenopausal women [6]. **How does PT-141 work?** PT-141 activates MC3R and MC4R receptors in the hypothalamus, bypassing vascular pathways entirely. Unlike PDE-5 inhibitors, it acts centrally on dopaminergic pathways linked to sexual motivation rather than on genital blood flow [11, 15]. MC4R activation in the medial preoptic area (mPOA) enhances presynaptic dopamine release, shifting the excitatory-inhibitory balance in brain arousal circuits toward desire initiation [15]. **How long does PT-141 last?** Clinical trial data indicates effects lasting approximately 6–12 hours in human subjects, with onset typically 30–60 minutes after subcutaneous administration [7, 8]. The 1.75 mg SC dose has a plasma half-life of approximately 2.5 hours; blood pressure effects resolved within 12 hours in ambulatory monitoring studies [8]. **What is PT-141 half-life?** Plasma half-life of bremelanotide in human pharmacokinetic studies is approximately 2.5 hours (range 1.9–2.7 hours across studies) [7]. Tmax is approximately 1 hour post SC injection. Peak plasma concentration after 1.75 mg SC is approximately 72.8 ng/mL [7]. **Is PT-141 FDA-approved?** Bremelanotide (the INN for PT-141) received FDA approval in June 2019 (NDA 210557) under the trade name Vyleesi for treatment of acquired, generalized HSDD in premenopausal women. The approved dose is 1.75 mg SC, maximum 1 dose per 24 hours, maximum 8 doses per month [6]. PT-141 is not FDA-approved for erectile dysfunction, postmenopausal women, or any male indication. **What are PT-141 side effects observed in studies?** The most common adverse events in Phase 3 bremelanotide trials were nausea (40.0% vs. 1.3% placebo), flushing (20.3% vs. 0.3%), and headache (11.3% vs. 1.9%) [9]. Transient systolic blood pressure increases of 3.1–3.2 mmHg were documented in ambulatory monitoring [8]. Hyperpigmentation (face, gums, breast) was observed with consecutive daily research-protocol dosing [9]. **How does PT-141 compare to PDE-5 inhibitors?** PT-141 acts centrally on melanocortin receptors in the CNS to modulate desire and arousal initiation, while PDE-5 inhibitors act peripherally on vascular smooth muscle. Phase 2 studies show PT-141 produced responses in subjects who did not respond to sildenafil [2], demonstrating the central and peripheral pathways are independent. Unlike PDE-5 inhibitors, bremelanotide produces transient blood pressure increases (not decreases) [8]. **Does PT-141 increase testosterone?** PT-141 does not operate via the hypothalamic-pituitary-gonadal axis and does not directly modulate testosterone production. It acts through MC3R/MC4R in the CNS. No significant testosterone elevation has been reported in clinical trial data. **Does PT-141 cause skin darkening?** PT-141 acts at MC1R at higher doses or higher dosing frequencies, which governs melanogenesis. Clinical trials and post-market data for bremelanotide document focal hyperpigmentation (face, gums, breast) as an adverse event. In research protocols using consecutive daily dosing for 16 days, over one-third of subjects developed hyperpigmentation. At label-compliant frequency (maximum 8 doses/month), hyperpigmentation was rare [9]. **What receptors does PT-141 target?** PT-141 is a non-selective melanocortin receptor agonist with primary activity at MC3R and MC4R, concentrated in the hypothalamus and limbic system. MC4R activation in the mPOA is believed responsible for the pro-sexual effects [15]. MC1R is activated at higher doses, accounting for the hyperpigmentation adverse event via melanogenesis [9]. A 2023 mouse study confirmed MC4R signaling in Sim1 hypothalamic neurons is sufficient for sexual receptivity [18]. **What does PT-141 research show for hypoactive sexual desire disorder?** The Phase 3 RECONNECT trials (NCT02333071, NCT02338960) demonstrated statistically significant increases in satisfying sexual events per month and reductions in FSDS-DAO distress scores versus placebo in premenopausal women with HSDD [5]. Response rates were approximately 58% bremelanotide vs. 36% placebo. Efficacy was consistent across demographic subgroups [5]. **Is PT-141 safe based on available research?** The clinical trial safety database includes ~3,500 subjects across 43 trials. Major concerns: nausea (~40%), transient blood pressure elevation (contraindication in uncontrolled hypertension), and hyperpigmentation at high-frequency dosing [9, 8]. At label-compliant frequency, the 52-week extension data showed no new safety signals through 76 weeks total exposure [14]. No deaths were reported in the clinical program [9]. ## References [1] Diamond LE, et al. Double-blind evaluation of intranasal PT-141. Int J Impotence Research. 2004. https://pubmed.ncbi.nlm.nih.gov/14963471/ [2] Rosen RC, et al. Evaluation of subcutaneous PT-141. Int J Impotence Research. 2004. https://pubmed.ncbi.nlm.nih.gov/14999221/ [5] Simon JA, et al. RECONNECT Phase 3 subgroup analyses. Journal of Women's Health. 2022. https://pubmed.ncbi.nlm.nih.gov/35230162/ [6] Mayer D, Lynch SE. Bremelanotide: New Drug Approved for HSDD. Annals of Pharmacotherapy. 2020. https://pubmed.ncbi.nlm.nih.gov/31893927/ [7] Edinoff AN, et al. Bremelanotide for Treatment of Female HSDD. Neurology International. 2022. https://pmc.ncbi.nlm.nih.gov/articles/PMC8788464/ [8] White WB, et al. Ambulatory blood pressure monitoring for bremelanotide. Journal of Hypertension. 2017. https://pubmed.ncbi.nlm.nih.gov/27977473/ [9] Clayton AH, et al. Safety Profile of Bremelanotide. Journal of Women's Health. 2022. https://pubmed.ncbi.nlm.nih.gov/35147466/ [11] Shadiack AM, et al. Melanocortins in male and female sexual dysfunction. Current Topics in Medicinal Chemistry. 2007. https://pubmed.ncbi.nlm.nih.gov/17584134/ [14] Simon JA, et al. Long-Term Safety and Efficacy of Bremelanotide. Obstetrics and Gynecology. 2019. https://pubmed.ncbi.nlm.nih.gov/31599847/ [15] Pfaus JG, et al. Neurobiology of bremelanotide for HSDD. CNS Spectrums. 2022. https://pubmed.ncbi.nlm.nih.gov/33455598/ [18] Semple EA, et al. MC4R signaling in Sim1 neurons. Frontiers in Endocrinology. 2023. https://pmc.ncbi.nlm.nih.gov/articles/PMC10080118/ --- Coin-operated reading room for the bremelanotide literature — every trial catalogued, no clinical service rendered.